MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
46.98
-1.50
-3.09%
After Hours: 46.98 0 0.00% 19:34 07/20 EDT
OPEN
48.48
PREV CLOSE
48.48
HIGH
49.46
LOW
46.21
VOLUME
406.85K
TURNOVER
--
52 WEEK HIGH
94.90
52 WEEK LOW
15.80
MARKET CAP
3.34B
P/E (TTM)
-17.2524
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GPCR last week (0713-0717)?
Weekly Report · 21h ago
Structure Therapeutics CSO Lin Xichen disposes of USD 401,255.43 in common shares
PUBT · 5d ago
Weekly Report: what happened at GPCR last week (0706-0710)?
Weekly Report · 07/13 09:08
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
Seeking Alpha · 07/09 12:46
Weekly Report: what happened at GPCR last week (0629-0703)?
Weekly Report · 07/06 09:09
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
NASDAQ · 07/03 13:12
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Seeking Alpha · 06/30 18:32
Weekly Report: what happened at GPCR last week (0622-0626)?
Weekly Report · 06/29 09:08
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.